GABA-ergic drugs: Exit stage left, enter stage right

Journal of Psychopharmacology

Volumn 17, Issue 2, 2003, Pages 174-178

  Ashton, Heather ^a   Young, Allan H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Affective disorders; Anticonvulsants; Anxiety disorders; Chronic pain; GABA ergic drugs; Gabapentin; Lamotrigine; Pregabalin; Tiagabine; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; LAMOTRIGINE; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADULT; AGORAPHOBIA; ANIMAL MODEL; ANTICONVULSANT THERAPY; ANXIETY DISORDER; BIPOLAR DEPRESSION; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MANIA; MENTAL DISEASE; MOOD DISORDER; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PAIN; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RASH; REVIEW; SIDE EFFECT; SOCIAL PHOBIA; STEVENS JOHNSON SYNDROME; SUICIDE; TRANQUILIZING ACTIVITY; TRIGEMINUS NEURALGIA; VISUAL FIELD DEFECT; WITHDRAWAL SYNDROME;

ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; EPILEPSY; GABA AGONISTS; HUMANS;

EID: 0038677031     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881103017002004     Document Type: Review

References (59)

1. Ashton C H, Rawlins M D, Tyrer S P (1990) A double-blind placebocontrolled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 157: 232-238
2. Ashton H (2002) Benzodiazepine abuse. In Caan W, de Belleroche J (eds), Drink, drugs and dependence: from science to clinical practice. Routledge, London
3. Brodie M J, Richens A, Yuen A W C (1995) Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345: 476-479
4. Bryans J S, Wustrow D J (1999) 3-substituted GABA analogues with central nervous system activity: a review. Med Res Rev 19: 149-177
5. Calabrese J R, Shelton M D, Rapport D J, Kimmell S E, Elhaj O (2002) Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry 63(Suppl 10): 18-22
6. Carta M G, Hardoy M C, Grunze H, Carpiniello B (2002) The use of tiagabine in affective disorders. Pharmacopsychiatry 35: 33-34
7. Carter R B, Wood P L, Wieland S, Hawkinson J E, Belleli D, Lambert J J, White H S, Wolf H H, Mersedeghi S, Tahir S H, Bolger N B, Lan N C, Gee K W (1997) Characterisation of the anticonvulsant properties of ganaxolone (CCD 1042 3alphahydroxy-3beta-methyl-5alpha-pregnan-20one), a selective high affinity, steroid modulator of the gamma-aminobutyric acis (A) receptor. J Pharmacol Exp Ther 280: 1284-1295
8. Cavallaro R, Regazzetti M G, Smeralid E (1993) Tolerance and withdrawal with zolpidem. Lancet 342: 374-375
9. Cochrane Database Systematic Review (2002) Antidepressant and benzodiazepine for major depression (1): CD00 1026
10. Committee on Safety of Medicines (1988) Benzodiazepines, dependence and withdrawal symptoms. Curr Problems 21: 1-2
11. Committee on Safety of Medicines (1998) Vigabatrin (Sabril) and visual field defects. Curr Prob Pharmacovig 24: 1
12. Covington E C (1998) Anticonvulsants for neuropathic pain and detoxification. Cleve Clin J Med 65(Suppl 1): S121-S129
13. Crawford P (1994) Managing therapy and possible problems, Prescriber 5(4): 31-36
14. Crockford D, White W D, Cambell B (2001) Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatry 46: 287
15. Czuczwar S J, Patsalos P N (2001) The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 15: 339-350
16. Dimond K R, Pande A C, Lamoreaux L, Pierce M W (1996) Effect of gabapentin (Neurontin) on mood and well-being in patients with epilepsy, Prog NeuroPsychopharmacol Biol Psychiatry 20: 407-417
17. Dodrill C B, Arnett J L, Sommerville K W, Shu V (1997) Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 4, 1025-1031
18. Drug and Therapeutics Bulletin (1980) The CRM on benzodiazepines. Drug Therap Bull 24: 97-98
19. Eke T, Talbot J F, Lawdon M C (1977) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314: 180-181
20. Ferrier I N (1998) Lamotrigine and gabapentin - alternatives in the treatment of bipolar disorder. Neuropsychobiology 38: 192-197
21. Field M J, Oles R J, Singh L (2001) Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 132: 1-4
22. Frye M A, Ketter T A, Kimbrell T A, Dunn R T, Speer A M, Osuch E A et al. (2000) A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20: 607-614
23. Hallstrom C, Lader M (1981) Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry 16: 235-244
24. Jefferson JW (2001) Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 62: 50-53
25. Jensen A A, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen T N, Abrahamsen B, Mattsson JP, Lehmann A, Bettler B, Braunder-Osborne H (2002) The anticonvulsant gabapentin (Neurontin) does not act through γ-aminobutyric acid-B receptors. Mol Pharmacol 61: 1377-1384
26. Jones I R, Sullivan S (1998) Physical dependence on zopiclone: case reports. Br Med J 316: 117
27. Kapetanovic I M, Yonekawa W D S, Kupferberg H J (1995) The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 22: 167-173
28. Kasper S, Blagdon M, Seghers S, Voorman A, Volz H P, Geniaux A, Struh N, Marchand A, Malsonobe P, Mikkelsen H (2002) A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. Poster presented at Annual Meeting of the American Psychiatric Association, Philadelphia, PA
29. Lader M (1987) Long-term benzodiazepine use and psychological functioning. In Freeman H, Rue Y (eds), The benzodiazepines in current clinical practice. International Congresss and Symposium Series, Royal Society of Medicine Services, London and New York
30. Lader M W, Petursson H (1981) Benzodiazepine derivatives - side effects and dangers. Biol Psychiatry 16: 1195-1212
31. Leach J P, Brodie M J (1998) Tiagabine. Lancet 351: 203-207
32. Leach M J, Marsden C M, Miller A A (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II Neurochemical studies on the mechanism of action. Epilepsia 27: 490-497
33. Leach J P, Girvan J, Paul A, Brodie M J (1997) Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy J Neuro Neurosurg Psychiatry 62: 372-376
34. Lucki I, Rickels K, Geller A M (1986) Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 88: 426-433
35. Macdonald K J, Young L T (2002) Newer antiepileptic drugs in bipolar disorder: Rationale for use and role in therapy. CNS Drugs 16: 549-562
36. Messenheimer J, Mullens E C, Giorgi L, Young F (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Safety 18: 281-296
37. Olajide D, Lader M (1987) A comparative study of the efficacy of buspirone in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 7: 11-15
38. Pande A C, Davidson J R T, Jefferson J W, Janney C A, Katzelnick D J, Weisler R H, Greist J H, Sutherland S M (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19: 341-348
39. Pande A C, Crockatt J G (2000) Gabapentin in bipolar disorder: a placebo controlled trial of adjunctive therapy. Bipolar Disord 2: 249-255
40. Pande A C, Pollack M H, Crockatt J, Greiner G, Lydiard R B, Taylor C B, Dager S R, Shiovitz T (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20, 467-471
41. Perry E, Young A H (2002) Neurotransmitter networks. In Perry E, Ashton H, Young A (eds) Neurochemistry of consciousness. John Bejamins Publishing Company, Amsterdam and Philadelphia
42. Porter R, Ferrier N, Ashton H (1999) Anticonvulsants as mood stabilisers. Adv Psychiatr Treat 5: 96-103
43. Rao G P, Fat F A, Kyle G (1998) Study is needed of visual field defects associated with any long term antiepileptic drug. Br Med J 317: 206
44. Richens A (1992) New drugs for epilepsy: a rapidly changing scene. Acta Neurologica Scan 86(Suppl 140): 65-70
45. Rickels K, Pollack M H, Lydiard R B, Bielski R J, Feltner D E, Pande A C, Kavoussl R J (2002) Efficacy and safety of pregabalin and alprazolam in generalized anixety disorder. Poster presented at Annual Meeting of the American Psychiatric Association, Philadelphia, PA
46. Ring H A, Trimble M R, Costa D C (1992) Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiat 55: 758-761
47. Robertson J R, Ronald P J (1992) Prescribing benzodiazepines to drug misusers. Lancet 339: 1169-1170
48. Ryback R, Ryback L (1997) Gabapentin for behavioural dyscontrol. Am J Psychiatry 152: 1399
49. Selak I (2001) Pregabalin (Pfizer). Curr Opin Invest Drugs 21: 828-834
50. Sikdar S, Ruben S M (1996) Zopiclone abuse among polydrug users. Addiction 91: 285-286
51. Singh L, Field M J, Ferris P, Hunter J C, Oles R J, Williams R G, Woodruff G N (1996) The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-Serine. Psychopharmacology 127: 1-9
52. Soderpalm B (2002) Anticonvulsants: aspects of their mechanisms of action. Eur J Pain 6 (Suppl A): 3-9
53. Stanton S P, Keck P E, McElroy S L (1997) Treatment of acute mania with gabapentin. Am J Psychiatry 154: 287
54. Stein M B, Liebowitz M R, Lydiard R B, Pitts C D, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280: 708-713
55. Taylor C P, Gee N S, Su T-Z, Kocsis J D, Welty D F, Brown J P, Dooley D J, Boden P, Singh L (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29: 233-249.
56. Tyrer P, Rutherford D, Huggett T (1981) Benzodiazepine withdrawal symptoms and propranolol. Lancet 1: 520-522
57. Wheeler G (2002) Gabapentin (Pfizer). Curr Opin Invest Drugs 3: 470-477
58. Yatham L N, Kusumakar V, Calabrese J R, Rao R, Scarrow G, Kroeker G (2002) Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 63: 275-283
59. Young A, Haddad P (2000) Discontinuation symptoms and psychotropic drugs. Lancet 355: 1184